beta-lapachone has been researched along with Neoplasms in 40 studies
beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase
beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Agents, such as β-lapachone, that target the redox enzyme, NAD(P)H:quinone oxidoreductase 1 (NQO1), to induce programmed necrosis in solid tumors have shown great promise, but more potent tumor-selective compounds are needed." | 3.78 | An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis. ( Bair, JS; Bey, EA; Boothman, DA; Dong, Y; Gao, J; Hergenrother, PJ; Huang, X; Kilgore, JA; Li, LS; Parkinson, EI; Patel, M; Wang, Y; Williams, NS, 2012) |
| "Herein, the multifaceted anticancer mechanism of LAP is briefly introduced, the advance of nanocarriers for LAP delivery is reviewed, and the combinational delivery approaches to enhance LAP potency in recent years are summarized." | 3.01 | Tailored Beta-Lapachone Nanomedicines for Cancer-Specific Therapy. ( Feng, M; Guo, T; Li, Y; Wang, Z; Zhao, Y, 2023) |
| " A brief history of these compounds is reviewed along with their potential effects and mechanisms of action and the most recent attempts to improve their bioavailability and potency against different types of cancer." | 2.66 | Anticancer Potential of Resveratrol, β-Lapachone and Their Analogues. ( Ferraz da Costa, DC; Ferreira, VF; Ferretti, GDDS; Martins-Dinis, MMDDC; Pereira Rangel, L; Silva, JL, 2020) |
| "Leishmania and cancer, reactions including copper-catalyzed azide-alkyne cycloaddition (click chemistry), palladium-catalysed cross couplings, C-H activation reactions, Ullmann couplings and heterocyclisations reported up to July 2019 will be discussed." | 2.61 | Synthesis of quinones with highlighted biological applications: A critical update on the strategies towards bioactive compounds with emphasis on lapachones. ( Ackermann, L; da Silva Júnior, EN; de Castro, SL; Dhawa, U; Jacob, C; Jardim, GAM, 2019) |
| "It is abnormally overexpressed in many tumors and intimately linked with multiple carcinogenic processes." | 2.58 | NAD(P)H:Quinone Oxidoreductase 1 (NQO1) as a Therapeutic and Diagnostic Target in Cancer. ( Chen, D; Hao, H; Jiang, S; Ma, K; Wu, X; Zhang, K, 2018) |
| "Current cancer chemotherapy lacks specificity and is limited by undesirable toxic side-effects, as well as a high rate of recurrence." | 2.52 | Nanotechnology-enabled delivery of NQO1 bioactivatable drugs. ( Boothman, DA; Gao, J; Huang, G; Huang, X; Ma, X; Moore, ZR, 2015) |
| "The first concerns the treatment of cancer by activating genome surveillance circuitry, namely checkpoint-pathway activation therapy." | 2.43 | Therapeutic biology: checkpoint pathway activation therapy, HIV Tat, and transkingdom RNA interference. ( Li, CJ, 2006) |
| "It exerted anticancer efficacy via NAD(P)H:quinone oxidoreductase 1 (NQO1)-mediated futile redox cycling, resulting in potent cytotoxicity that was highly selective for NQO1-rich cancer cells over normal cells both in vitro and in vivo." | 1.72 | A Carbon-Carbon Bond Cleavage-Based Prodrug Activation Strategy Applied to β-Lapachone for Cancer-Specific Targeting. ( Gong, Q; Hu, J; Li, T; Li, X; Wu, X; Yang, F; Zhang, X, 2022) |
| "As part of their oncogenic status, cancer cells frequently produce increased levels of mitochondrial-generated reactive oxygen species (ROS)." | 1.42 | Mitochondrial targeted β-lapachone induces mitochondrial dysfunction and catastrophic vacuolization in cancer cells. ( Lim, C; Ma, J; Qian, W; Sacher, JR; Van Houten, B; Wipf, P, 2015) |
| "Regarding cytotoxic activity against cancer cell lines, it has been recognized as an important prototype." | 1.37 | Preclinical genotoxicology of nor-β-lapachone in human cultured lymphocytes and Chinese hamster lung fibroblasts. ( Barros, FW; Cabral, IO; Cavalcanti, BC; Costa, CO; da Silva Júnior, EN; de Abreu, FC; Ferreira, JR; Goulart, MO; Júnior, HV; Magalhães, HI; Moraes, MO; Pessoa, C, 2011) |
| "Growth of FSaII tumors in the hind legs of C3H mice was determined after treating the host mice with i." | 1.33 | Heat-induced up-regulation of NAD(P)H:quinone oxidoreductase potentiates anticancer effects of beta-lapachone. ( Ahn, KJ; Ahn, SD; Boothman, DA; Choi, EK; Choi, J; Griffin, R; Ji, IM; Kim, EJ; Kook, YH; Lee, CK; Park, HJ; Song, CW; Williams, B, 2005) |
| "Most chemotherapeutic drugs kill cancer cells by indirectly activating checkpoint-mediated apoptosis after creating nonselective damage to DNA or microtubules, which accounts for their toxicity toward normal cells." | 1.32 | Selective killing of cancer cells by beta -lapachone: direct checkpoint activation as a strategy against cancer. ( LaMont, JT; Li, CJ; Li, Y; Pardee, AB; Sun, X, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (30.00) | 29.6817 |
| 2010's | 16 (40.00) | 24.3611 |
| 2020's | 12 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Eyong, KO | 1 |
| Kumar, PS | 1 |
| Kuete, V | 1 |
| Folefoc, GN | 1 |
| Nkengfack, EA | 1 |
| Baskaran, S | 1 |
| Evdokimov, NM | 1 |
| Magedov, IV | 1 |
| McBrayer, D | 1 |
| Kornienko, A | 1 |
| Zhang, K | 1 |
| Chen, D | 1 |
| Ma, K | 1 |
| Wu, X | 2 |
| Hao, H | 1 |
| Jiang, S | 1 |
| da Silva Júnior, EN | 2 |
| Jardim, GAM | 1 |
| Jacob, C | 1 |
| Dhawa, U | 1 |
| Ackermann, L | 1 |
| de Castro, SL | 1 |
| Gong, Q | 2 |
| Hu, J | 2 |
| Wang, P | 1 |
| Li, X | 3 |
| Zhang, X | 2 |
| Feng, X | 1 |
| Liao, D | 1 |
| Liu, D | 1 |
| Ping, A | 1 |
| Li, Z | 1 |
| Bian, J | 1 |
| Furqan, M | 1 |
| Fayyaz, A | 1 |
| Firdous, F | 1 |
| Raza, H | 1 |
| Bilal, A | 1 |
| Saleem, RSZ | 1 |
| Shahzad-Ul-Hussan, S | 1 |
| Wang, D | 1 |
| Youssef, FS | 1 |
| Al Musayeib, NM | 1 |
| Ashour, ML | 1 |
| Hussain, H | 2 |
| Faisal, A | 1 |
| Liao, JX | 1 |
| Huang, QF | 1 |
| Li, YH | 1 |
| Zhang, DW | 1 |
| Wang, GH | 1 |
| Li, T | 1 |
| Yang, F | 1 |
| Wang, X | 1 |
| Liu, Y | 1 |
| Xue, C | 1 |
| Hu, Y | 1 |
| Zhao, Y | 2 |
| Cai, K | 1 |
| Li, M | 2 |
| Luo, Z | 1 |
| Li, Y | 3 |
| Feng, M | 1 |
| Guo, T | 1 |
| Wang, Z | 2 |
| Santos, VLDA | 1 |
| Gonsalves, AA | 1 |
| Guimarães, DG | 1 |
| Simplicio, SS | 1 |
| Oliveira, HP | 1 |
| Ramos, LPS | 1 |
| Costa, MPD | 1 |
| Oliveira, FCE | 1 |
| Pessoa, C | 2 |
| Araújo, CRM | 1 |
| Dal Forno, GM | 1 |
| Latocheski, E | 1 |
| Beatriz Machado, A | 1 |
| Becher, J | 1 |
| Dunsmore, L | 1 |
| St John, AL | 1 |
| Oliveira, BL | 1 |
| Navo, CD | 1 |
| Jiménez-Osés, G | 1 |
| Fior, R | 1 |
| Domingos, JB | 1 |
| Bernardes, GJL | 1 |
| Ferraz da Costa, DC | 1 |
| Pereira Rangel, L | 1 |
| Martins-Dinis, MMDDC | 1 |
| Ferretti, GDDS | 1 |
| Ferreira, VF | 2 |
| Silva, JL | 1 |
| Li, Q | 1 |
| Hou, W | 1 |
| Ye, H | 1 |
| Li, H | 1 |
| Su, X | 1 |
| Wang, J | 1 |
| Jiang, L | 2 |
| Chen, Y | 1 |
| Lu, T | 1 |
| Mendonca, MS | 1 |
| Huang, X | 4 |
| Green, IR | 1 |
| Gerber, DE | 1 |
| Beg, MS | 1 |
| Fattah, F | 1 |
| Frankel, AE | 1 |
| Fatunde, O | 1 |
| Arriaga, Y | 1 |
| Dowell, JE | 1 |
| Bisen, A | 1 |
| Leff, RD | 1 |
| Meek, CC | 1 |
| Putnam, WC | 1 |
| Kallem, RR | 1 |
| Subramaniyan, I | 1 |
| Dong, Y | 5 |
| Bolluyt, J | 1 |
| Sarode, V | 1 |
| Luo, X | 1 |
| Xie, Y | 1 |
| Schwartz, B | 1 |
| Boothman, DA | 9 |
| Liu, Z | 1 |
| Zhang, A | 1 |
| Han, C | 1 |
| Shen, A | 1 |
| Qiao, J | 1 |
| Wang, Y | 2 |
| Fu, YX | 1 |
| Morales, J | 1 |
| Li, L | 2 |
| Fattah, FJ | 1 |
| Bey, EA | 5 |
| Patel, M | 2 |
| Gao, J | 5 |
| Li, JZ | 1 |
| Ke, Y | 1 |
| Misra, HP | 1 |
| Trush, MA | 1 |
| Li, YR | 1 |
| Zhu, H | 1 |
| Jia, Z | 1 |
| Ma, J | 1 |
| Lim, C | 1 |
| Sacher, JR | 1 |
| Van Houten, B | 1 |
| Qian, W | 1 |
| Wipf, P | 1 |
| Ma, X | 1 |
| Moore, ZR | 1 |
| Huang, G | 1 |
| Nicoletti, CD | 1 |
| Ferreira, PG | 1 |
| Futuro, DO | 1 |
| da Silva, FC | 1 |
| Cavalcanti, BC | 1 |
| Barros, FW | 1 |
| Cabral, IO | 1 |
| Ferreira, JR | 1 |
| Magalhães, HI | 1 |
| Júnior, HV | 1 |
| de Abreu, FC | 1 |
| Costa, CO | 1 |
| Goulart, MO | 1 |
| Moraes, MO | 1 |
| Siegel, D | 1 |
| Yan, C | 1 |
| Ross, D | 1 |
| Kilgore, JA | 1 |
| Bair, JS | 1 |
| Li, LS | 1 |
| Parkinson, EI | 1 |
| Williams, NS | 1 |
| Hergenrother, PJ | 1 |
| Cunha-Filho, MS | 1 |
| Alvarez-Lorenzo, C | 1 |
| Martínez-Pacheco, R | 1 |
| Landin, M | 1 |
| He, T | 1 |
| Banach-Latapy, A | 1 |
| Vernis, L | 1 |
| Dardalhon, M | 1 |
| Chanet, R | 1 |
| Huang, ME | 1 |
| Pardee, AB | 2 |
| Li, YZ | 1 |
| Li, CJ | 4 |
| Sun, X | 2 |
| LaMont, JT | 1 |
| Fernández Villamil, S | 1 |
| Stoppani, AO | 2 |
| Dubin, M | 2 |
| Reinicke, KE | 3 |
| Bentle, MS | 3 |
| Pink, JJ | 2 |
| Ingalls, ST | 1 |
| Hoppel, CL | 1 |
| Misico, RI | 1 |
| Arzac, GM | 1 |
| Burton, G | 1 |
| Bornmann, WG | 1 |
| Sutton, D | 1 |
| Park, HJ | 1 |
| Choi, EK | 1 |
| Choi, J | 1 |
| Ahn, KJ | 1 |
| Kim, EJ | 1 |
| Ji, IM | 1 |
| Kook, YH | 1 |
| Ahn, SD | 1 |
| Williams, B | 1 |
| Griffin, R | 1 |
| Lee, CK | 1 |
| Song, CW | 1 |
| Li, W | 1 |
| Zhang, B | 1 |
| Wang, AJ | 1 |
| Sun, J | 1 |
| Mikule, K | 1 |
| Jiang, Z | 1 |
| Wuerzberger-Davis, SM | 1 |
| Yang, CR | 1 |
| Araki, S | 1 |
| Cataldo, E | 1 |
| Criswell, TL | 1 |
| Wagner, MW | 1 |
| Fernandez Villamil, SH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1 Dose Escalation and Pharmacodynamic Study of ARQ 761 (Beta-Lapachone) in Adult Patients With Advanced Solid Tumors[NCT01502800] | Phase 1 | 91 participants (Actual) | Interventional | 2011-12-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
18 reviews available for beta-lapachone and Neoplasms
| Article | Year |
|---|---|
NAD(P)H:Quinone Oxidoreductase 1 (NQO1) as a Therapeutic and Diagnostic Target in Cancer.
Topics: Antineoplastic Agents; Enzyme Inhibitors; Humans; Models, Molecular; Molecular Structure; NAD(P)H De | 2018 |
NAD(P)H:Quinone Oxidoreductase 1 (NQO1) as a Therapeutic and Diagnostic Target in Cancer.
Topics: Antineoplastic Agents; Enzyme Inhibitors; Humans; Models, Molecular; Molecular Structure; NAD(P)H De | 2018 |
Synthesis of quinones with highlighted biological applications: A critical update on the strategies towards bioactive compounds with emphasis on lapachones.
Topics: Animals; Antineoplastic Agents; Antiprotozoal Agents; Cell Line, Tumor; Cell Proliferation; Chagas D | 2019 |
Synthesis of quinones with highlighted biological applications: A critical update on the strategies towards bioactive compounds with emphasis on lapachones.
Topics: Animals; Antineoplastic Agents; Antiprotozoal Agents; Cell Line, Tumor; Cell Proliferation; Chagas D | 2019 |
A comprehensive review on β-lapachone: Mechanisms, structural modifications, and therapeutic potentials.
Topics: Animals; Anti-Infective Agents; Antineoplastic Agents; Drug Discovery; Humans; Naphthoquinones; Neop | 2021 |
A comprehensive review on β-lapachone: Mechanisms, structural modifications, and therapeutic potentials.
Topics: Animals; Anti-Infective Agents; Antineoplastic Agents; Drug Discovery; Humans; Naphthoquinones; Neop | 2021 |
Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective.
Topics: Binding Sites; Catalytic Domain; Drug Discovery; Enzyme Inhibitors; Humans; Indoleamine-Pyrrole 2,3, | 2020 |
Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective.
Topics: Binding Sites; Catalytic Domain; Drug Discovery; Enzyme Inhibitors; Humans; Indoleamine-Pyrrole 2,3, | 2020 |
Identification and Characterization of Natural and Semisynthetic Quinones as Aurora Kinase Inhibitors.
Topics: Anthraquinones; Aurora Kinase A; Aurora Kinase B; Cell Line, Tumor; DNA Helicases; Humans; Neoplasms | 2022 |
Identification and Characterization of Natural and Semisynthetic Quinones as Aurora Kinase Inhibitors.
Topics: Anthraquinones; Aurora Kinase A; Aurora Kinase B; Cell Line, Tumor; DNA Helicases; Humans; Neoplasms | 2022 |
Tailored Beta-Lapachone Nanomedicines for Cancer-Specific Therapy.
Topics: Antineoplastic Agents; Cell Line, Tumor; NAD(P)H Dehydrogenase (Quinone); Nanomedicine; Naphthoquino | 2023 |
Tailored Beta-Lapachone Nanomedicines for Cancer-Specific Therapy.
Topics: Antineoplastic Agents; Cell Line, Tumor; NAD(P)H Dehydrogenase (Quinone); Nanomedicine; Naphthoquino | 2023 |
Anticancer Potential of Resveratrol, β-Lapachone and Their Analogues.
Topics: Antineoplastic Agents; Humans; Inhibitory Concentration 50; Naphthoquinones; Neoplasms; Resveratrol; | 2020 |
Anticancer Potential of Resveratrol, β-Lapachone and Their Analogues.
Topics: Antineoplastic Agents; Humans; Inhibitory Concentration 50; Naphthoquinones; Neoplasms; Resveratrol; | 2020 |
Lapachol and lapachone analogs: a journey of two decades of patent research(1997-2016).
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Design; Humans; Naphthoquinones; | 2017 |
Lapachol and lapachone analogs: a journey of two decades of patent research(1997-2016).
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Design; Humans; Naphthoquinones; | 2017 |
Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases.
Topics: Animals; Disease Models, Animal; DNA Repair; Enzyme Inhibitors; Epigenesis, Genetic; Humans; Molecul | 2014 |
Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases.
Topics: Animals; Disease Models, Animal; DNA Repair; Enzyme Inhibitors; Epigenesis, Genetic; Humans; Molecul | 2014 |
Nanotechnology-enabled delivery of NQO1 bioactivatable drugs.
Topics: Animals; Antineoplastic Agents; Drug Delivery Systems; Drug Design; Humans; Maximum Tolerated Dose; | 2015 |
Nanotechnology-enabled delivery of NQO1 bioactivatable drugs.
Topics: Animals; Antineoplastic Agents; Drug Delivery Systems; Drug Design; Humans; Maximum Tolerated Dose; | 2015 |
Strategies for Increasing the Solubility and Bioavailability of Anticancer Compounds: β-Lapachone and Other Naphthoquinones.
Topics: Antineoplastic Agents, Phytogenic; Biological Availability; Biological Products; Cell Survival; Huma | 2016 |
Strategies for Increasing the Solubility and Bioavailability of Anticancer Compounds: β-Lapachone and Other Naphthoquinones.
Topics: Antineoplastic Agents, Phytogenic; Biological Availability; Biological Products; Cell Survival; Huma | 2016 |
NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.
Topics: Antineoplastic Agents; Benzoquinones; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; | 2012 |
NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.
Topics: Antineoplastic Agents; Benzoquinones; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; | 2012 |
Cancer therapy with beta-lapachone.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Brazil; Drug Therapy, Combi | 2002 |
Cancer therapy with beta-lapachone.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Brazil; Drug Therapy, Combi | 2002 |
Redox cycling of beta-lapachone and structural analogues in microsomal and cytosol liver preparations.
Topics: Animals; Antineoplastic Agents; Cytosol; Electron Spin Resonance Spectroscopy; Humans; Liver Extract | 2004 |
Redox cycling of beta-lapachone and structural analogues in microsomal and cytosol liver preparations.
Topics: Animals; Antineoplastic Agents; Cytosol; Electron Spin Resonance Spectroscopy; Humans; Liver Extract | 2004 |
New tricks for old drugs: the anticarcinogenic potential of DNA repair inhibitors.
Topics: Anticarcinogenic Agents; Cell Transformation, Neoplastic; DNA Breaks, Double-Stranded; DNA Breaks, S | 2006 |
New tricks for old drugs: the anticarcinogenic potential of DNA repair inhibitors.
Topics: Anticarcinogenic Agents; Cell Transformation, Neoplastic; DNA Breaks, Double-Stranded; DNA Breaks, S | 2006 |
Therapeutic biology: checkpoint pathway activation therapy, HIV Tat, and transkingdom RNA interference.
Topics: AIDS Vaccines; Animals; Gene Products, tat; Genes, cdc; Genomics; Humans; Lymphocyte Activation; Nap | 2006 |
Therapeutic biology: checkpoint pathway activation therapy, HIV Tat, and transkingdom RNA interference.
Topics: AIDS Vaccines; Animals; Gene Products, tat; Genes, cdc; Genomics; Humans; Lymphocyte Activation; Nap | 2006 |
Mornings with Art, lessons learned: feedback regulation, restriction threshold biology, and redundancy govern molecular stress responses.
Topics: Apoptosis; Cell Cycle; Cell Death; Cell Physiological Phenomena; Clusterin; DNA Mismatch Repair; Fee | 2006 |
Mornings with Art, lessons learned: feedback regulation, restriction threshold biology, and redundancy govern molecular stress responses.
Topics: Apoptosis; Cell Cycle; Cell Death; Cell Physiological Phenomena; Clusterin; DNA Mismatch Repair; Fee | 2006 |
[Cytotoxicity of beta-lapachone, an naphthoquinone with possible therapeutic use].
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Carcinoma 256, Walker; Humans; Naphthoquinones; Neo | 2001 |
[Cytotoxicity of beta-lapachone, an naphthoquinone with possible therapeutic use].
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Carcinoma 256, Walker; Humans; Naphthoquinones; Neo | 2001 |
1 trial available for beta-lapachone and Neoplasms
| Article | Year |
|---|---|
Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Cell Line, Tumor; DNA Damage; Female; Humans; Male; Middl | 2018 |
Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Cell Line, Tumor; DNA Damage; Female; Humans; Male; Middl | 2018 |
21 other studies available for beta-lapachone and Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Semisynthesis and antitumoral activity of 2-acetylfuranonaphthoquinone and other naphthoquinone derivatives from lapachol.
Topics: Aldehydes; Antineoplastic Agents; Cell Line, Tumor; Chemistry, Pharmaceutical; Dose-Response Relatio | 2008 |
Semisynthesis and antitumoral activity of 2-acetylfuranonaphthoquinone and other naphthoquinone derivatives from lapachol.
Topics: Aldehydes; Antineoplastic Agents; Cell Line, Tumor; Chemistry, Pharmaceutical; Dose-Response Relatio | 2008 |
Isatin derivatives with activity against apoptosis-resistant cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, | 2016 |
Isatin derivatives with activity against apoptosis-resistant cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, | 2016 |
Chitosan derivatives functionalized dual ROS-responsive nanocarriers to enhance synergistic oxidation-chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Chitosan; Doxorubicin; Drug Carriers; D | 2022 |
Chitosan derivatives functionalized dual ROS-responsive nanocarriers to enhance synergistic oxidation-chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Chitosan; Doxorubicin; Drug Carriers; D | 2022 |
A Carbon-Carbon Bond Cleavage-Based Prodrug Activation Strategy Applied to β-Lapachone for Cancer-Specific Targeting.
Topics: Antineoplastic Agents; Biological Products; Carbon; Cell Line, Tumor; NAD; NAD(P)H Dehydrogenase (Qu | 2022 |
A Carbon-Carbon Bond Cleavage-Based Prodrug Activation Strategy Applied to β-Lapachone for Cancer-Specific Targeting.
Topics: Antineoplastic Agents; Biological Products; Carbon; Cell Line, Tumor; NAD; NAD(P)H Dehydrogenase (Qu | 2022 |
A protein-based cGAS-STING nanoagonist enhances T cell-mediated anti-tumor immune responses.
Topics: DNA; Ferritins; Humans; Immunity, Innate; Manganese; Mannose; Membrane Proteins; Naphthoquinones; Ne | 2022 |
A protein-based cGAS-STING nanoagonist enhances T cell-mediated anti-tumor immune responses.
Topics: DNA; Ferritins; Humans; Immunity, Innate; Manganese; Mannose; Membrane Proteins; Naphthoquinones; Ne | 2022 |
Naphth[1,2-
Topics: Antineoplastic Agents; Cytotoxins; Fluorescent Dyes; Humans; Imidazoles; Neoplasms; Structure-Activi | 2023 |
Naphth[1,2-
Topics: Antineoplastic Agents; Cytotoxins; Fluorescent Dyes; Humans; Imidazoles; Neoplasms; Structure-Activi | 2023 |
Expanding Transition Metal-Mediated Bioorthogonal Decaging to Include C-C Bond Cleavage Reactions.
Topics: Animals; Humans; Naphthoquinones; Neoplasms; Palladium; Prodrugs; Zebrafish | 2023 |
Expanding Transition Metal-Mediated Bioorthogonal Decaging to Include C-C Bond Cleavage Reactions.
Topics: Animals; Humans; Naphthoquinones; Neoplasms; Palladium; Prodrugs; Zebrafish | 2023 |
Ultrasound Combined with Core Cross-Linked Nanosystem for Enhancing Penetration of Doxorubicin Prodrug/Beta-Lapachone into Tumors.
Topics: Animals; Boronic Acids; Capillary Permeability; Cell Death; Cross-Linking Reagents; Doxorubicin; Dru | 2020 |
Ultrasound Combined with Core Cross-Linked Nanosystem for Enhancing Penetration of Doxorubicin Prodrug/Beta-Lapachone into Tumors.
Topics: Animals; Boronic Acids; Capillary Permeability; Cell Death; Cross-Linking Reagents; Doxorubicin; Dru | 2020 |
PCNA inhibition enhances the cytotoxicity of β-lapachone in NQO1-Positive cancer cells by augmentation of oxidative stress-induced DNA damage.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; | 2021 |
PCNA inhibition enhances the cytotoxicity of β-lapachone in NQO1-Positive cancer cells by augmentation of oxidative stress-induced DNA damage.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; | 2021 |
NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance.
Topics: A549 Cells; Animals; Cell Line, Tumor; Humans; Immunity, Innate; Mice, Inbred C57BL; Mice, Inbred NO | 2019 |
NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance.
Topics: A549 Cells; Animals; Cell Line, Tumor; Humans; Immunity, Innate; Mice, Inbred C57BL; Mice, Inbred NO | 2019 |
Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent.
Topics: Activation, Metabolic; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Electron Transp | 2014 |
Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent.
Topics: Activation, Metabolic; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Electron Transp | 2014 |
Mitochondrial targeted β-lapachone induces mitochondrial dysfunction and catastrophic vacuolization in cancer cells.
Topics: Apoptosis; Cell Death; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Humans; Mi | 2015 |
Mitochondrial targeted β-lapachone induces mitochondrial dysfunction and catastrophic vacuolization in cancer cells.
Topics: Apoptosis; Cell Death; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Humans; Mi | 2015 |
Preclinical genotoxicology of nor-β-lapachone in human cultured lymphocytes and Chinese hamster lung fibroblasts.
Topics: Animals; Antineoplastic Agents; Cell Survival; Cells, Cultured; Cricetinae; DNA; DNA Damage; Fibrobl | 2011 |
Preclinical genotoxicology of nor-β-lapachone in human cultured lymphocytes and Chinese hamster lung fibroblasts.
Topics: Animals; Antineoplastic Agents; Cell Survival; Cells, Cultured; Cricetinae; DNA; DNA Damage; Fibrobl | 2011 |
An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Calcium; Cell Line, Tumor; DNA Damage; Egtazic Acid; | 2012 |
An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Calcium; Cell Line, Tumor; DNA Damage; Egtazic Acid; | 2012 |
Temperature-sensitive gels for intratumoral delivery of β-lapachone: effect of cyclodextrins and ethanol.
Topics: Cyclodextrins; Delayed-Action Preparations; Diffusion; Ethanol; Gels; Humans; Materials Testing; Nap | 2012 |
Temperature-sensitive gels for intratumoral delivery of β-lapachone: effect of cyclodextrins and ethanol.
Topics: Cyclodextrins; Delayed-Action Preparations; Diffusion; Ethanol; Gels; Humans; Materials Testing; Nap | 2012 |
Peroxiredoxin 1 knockdown potentiates β-lapachone cytotoxicity through modulation of reactive oxygen species and mitogen-activated protein kinase signals.
Topics: Apoptosis; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; HeLa Cells; Humans; Hydroge | 2013 |
Peroxiredoxin 1 knockdown potentiates β-lapachone cytotoxicity through modulation of reactive oxygen species and mitogen-activated protein kinase signals.
Topics: Apoptosis; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; HeLa Cells; Humans; Hydroge | 2013 |
Selective killing of cancer cells by beta -lapachone: direct checkpoint activation as a strategy against cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell C | 2003 |
Selective killing of cancer cells by beta -lapachone: direct checkpoint activation as a strategy against cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell C | 2003 |
Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels.
Topics: Cell Division; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; Dose-Response | 2005 |
Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels.
Topics: Cell Division; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; Dose-Response | 2005 |
Heat-induced up-regulation of NAD(P)H:quinone oxidoreductase potentiates anticancer effects of beta-lapachone.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Combined Modality Therapy; Dicumarol; | 2005 |
Heat-induced up-regulation of NAD(P)H:quinone oxidoreductase potentiates anticancer effects of beta-lapachone.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Combined Modality Therapy; Dicumarol; | 2005 |
Selective induction of necrotic cell death in cancer cells by beta-lapachone through activation of DNA damage response pathway.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; DNA Damage; Female; HeLa Cells; Humans; Mice; Mice | 2006 |
Selective induction of necrotic cell death in cancer cells by beta-lapachone through activation of DNA damage response pathway.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; DNA Damage; Female; HeLa Cells; Humans; Mice; Mice | 2006 |